On Wednesday, September 7, 2022, Dr. Michael Hayden, CEO of Prilenia, along with Drs. Andy Feigin and Sandra Kostyk, provided an overview and insights into the progress of PROOF-HD, a global, Phase 3 study evaluating pridopidine for the treatment of #HuntingtonsDisease.
#LetsTalkAboutHD #HDSAFamily
source
